This article was provided by the Institute of Entrepreneurship and Private Capital whose aim is to inspire entrepreneurs and investors to pursue impactful innovation by equipping them with the tools, expertise and insights to drive growth.
IIEKilling innovation in the pharmaceutical industry
Why do big pharma incumbents buy startups? LBS research finds major players may be protecting their market power
“Do incumbent companies really acquire emerging competitors for the purpose of shutting them down?”
“The acquisition-to-kill strategy can be profit-maximising for an incumbent and the incentive is at its highest when the market overlap is high and the product development overlap is low”
